Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GEXVal Focuses On Rare Diseases As It Builds On Ex-Takeda Assets

Executive Summary

Emerging Company Profile: Japanese company GEXVal is one of several bioventures formed from the spin-out of researchers and assets from Takeda, and is focused on bringing therapies of value to patients with rare diseases, including a novel molecule for pulmonary arterial hypertension.

You may also be interested in...



Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: the biggest drug launches expected in 2024; Roche’s Pharma CEO talks about growth momentum; 10 pivotal studies to look out for this year; the obesity market now and in future; and what does 2024 hold for transformative technology in biopharma.  

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Bayer’s pipeline refresh; J&J’s selective pharma M&A approach; silver lining for Gilead’s Trodelvy miss?; paying for obesity drugs; and the story behind Vertex and CRISPR’s gene therapy breakthrough. 

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: major takeaways and highlights from the JP Morgan meeting; J&J bets on ADCs with Ambrx buy; the Indian GLP-1 battleground; and Scrip asks what 2024 holds for business strategy and leadership.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC125124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel